Novel oral anticoagulants in the treatment of cerebral venous thrombosis

Gergely Feher, Zsolt Illes, Samuel Komoly, David Hargroves

Research output: Review article

1 Citation (Scopus)

Abstract

Cerebral venous thrombosis (CVT) is an uncommon cause of stroke with extremely diverse clinical features, predisposing factors, brain imaging findings, and outcome. Anticoagulation is the cornerstone of CVT management, however, it is not supported by high-quality evicence. Novel oral anticoagulants (NOACs) have been extensively studied in patients with deep vein thrombosis, pulmonary embolism and non-valvular atrial fibrillation. The aim of our work was to review the available evidence for NOACs in the treatment of CVT. Based on our literature search there is insufficient evidence to support the use of NOACs in CVT, although case series with rivaroxaban and dabigatran have showed promising results.

Original languageEnglish
Pages (from-to)365-368
Number of pages4
JournalInternational Angiology
Volume35
Issue number4
Publication statusPublished - aug. 2016

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Novel oral anticoagulants in the treatment of cerebral venous thrombosis'. Together they form a unique fingerprint.

  • Cite this